Previous 10 | Next 10 |
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors PR Newswire Data demonstrates compelling clinical activity, highlights adagrasib potential as monothera...
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023 PR Newswire SAN DIEGO , April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, wil...
2023-04-13 00:30:00 ET Summary In the Russell 1,000, 33 names are up more than 1,000% since April 12th, 2013. Over the same 10-year period, the S&P 500 tracking ETF is up 211%. The obvious next question is: which stocks will be ten baggers over the next ten years? ...
2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs PR Newswire Preclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options SAN DIEGO , April...
2023-03-20 03:43:10 ET Summary Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approved product. Krazati is used to treat adult patients with KRAS G12C-mutated locally advanced or metast...
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference PR Newswire SAN DIEGO , March 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Barclays Global H...
Mirati Therapeutics, Inc. (MRTX) Q4 2022 Earnings Conference Call February 28, 2023, 04:30 PM ET Company Participants Ryan Asay - VP of Corporate Affairs David Meek - CEO Charles Baum - President, Founder and Head of R&D Laurie Stelzer - CFO James Christens...
Mirati Therapeutics press release ( NASDAQ: MRTX ): Q4 GAAP EPS of -$3.51 beats by $0.16 . Revenue of $0.93M (+210.0% Y/Y) misses by $1.72M . For further details see: Mirati Therapeutics GAAP EPS of -$3.51 beats by $0.16, revenue of $0.93M misses by $1.72M
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...